What does CJC-1295 with DAC stack well with?

For female physiology protocols, CJC-1295 with DAC pairs with compounds on complementary pathways: Oxytocin, Kisspeptin, GHK-Cu. These pairings are selected because they engage independent receptor systems from CJC-1295 with DAC's primary mechanism (Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release), producing additive or synergistic effects rather than receptor competition.

What route should I use for CJC-1295 with DAC?

CJC-1295 with DAC is delivered by subq. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

What is the evidence base for CJC-1295 with DAC?

CJC-1295 with DAC's evidence base sits at phase ii human data; widely used off-label. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The female physiology interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What should I look for in CJC-1295 with DAC sourcing and quality?

Acceptable CJC-1295 with DAC certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching ~3367 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What is the regulatory status of CJC-1295 with DAC?

CJC-1295 with DAC regulatory status: Unapproved in the United States; WADA status banned (s2 class); research level phase ii human data; widely used off-label. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For female hormonal and cyclical use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Home/ Compounds/ CJC-1295 with DAC

CJC-1295 with DAC

Women's Health

For women considering CJC-1295 with DAC, the framework spans three life stages: reproductive, perimenopausal, and postmenopausal. Each carries distinct hormonal context and distinct monitoring requirements. A long-acting growth-hormone-releasing-hormone analogue with a Drug Affinity Complex that extends half-life to roughly a week. The ~6-8 days (with DAC) pharmacokinetic profile shapes how the compound is felt across follicular versus luteal phases in pre-menopausal users and how it integrates with HRT in older cohorts.

Female Physiology Applications

MenopauseEndometriosis SupportPerimenopauseBody Composition (Female)Autoimmune Support

Key Takeaways

Female-physiology lens: CJC-1295 with DAC response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 1-2 mg 1-2x weekly via subq; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1. Female-physiology implications operate across three life-stage contexts: pre-menopausal cyclical users, the perimenopausal transition, and post-menopausal users on or off HRT. CJC-1295 with DAC's response varies meaningfully across these contexts, as the subsections on cyclical context, perimenopause integration, fertility, and bone-and-cardiovascular signalling describe.

Fertility and reproductive considerations

CJC-1295 with DAC's effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. CJC-1295 with DAC's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and CJC-1295 with DAC's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Female Physiology Applications

Cardiovascular (Female)

Cardiovascular (Female) is one of the dimensions on which women track CJC-1295 with DAC response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Fertility

In the perimenopausal window, CJC-1295 with DAC for fertility produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Skin Health

For skin health in female users, CJC-1295 with DAC is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Body Composition (Female)

Body Composition (Female) is one of the dimensions on which women track CJC-1295 with DAC response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1-2 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-2 mg	4–6 weeks initial cycle
Women's Health focus	SubQ	1-2 mg	1-2x weekly
Maintenance phase	SubQ	1-2 mg	Ongoing with periodic pauses

Dose timing for CJC-1295 with DAC is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

CJC-1295 with DAC stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

CJC-1295 with DAC + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with CJC-1295 with DAC's mechanism in female physiology protocols.
CJC-1295 with DAC + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with CJC-1295 with DAC's mechanism in female physiology protocols.
CJC-1295 with DAC + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with CJC-1295 with DAC's mechanism in female physiology protocols.
CJC-1295 with DAC + Epithalon: Identified by Khavinson in St. Pairs naturally with CJC-1295 with DAC's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Banned (S2 class) FDA: Unapproved Research: Phase II human data; widely used off-label

Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible.

Lens-specific safety considerations for female physiology use of CJC-1295 with DAC: Sustained IGF-1 elevation; monitor in users at risk of malignancy. Site reactions, transient flushing, water retention possible. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

CJC-1295 sustained release of growth hormone in healthy adults

PMID 16940290

Supporting

Long-acting GHRH analogue mechanism and pharmacokinetics

PMID 16352683

CJC-1295 with DAC vs Related Peptides

Compound	Profile	Onset	Best For
CJC-1295 with DAC	Long-acting GHRH analogue	~6-8 days (with DAC)	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Is CJC-1295 with DAC appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

Will CJC-1295 with DAC affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. CJC-1295 with DAC's specific interaction follows its mechanism.

Does CJC-1295 with DAC affect bone density?

Several peptide compounds have measurable effects on bone-remodelling markers, particularly relevant for post-menopausal users. Where CJC-1295 with DAC specifically engages this pathway, paired pre-post DEXA or bone-marker tracking provides the cleanest evaluation. For most compounds the bone effect is secondary and develops over months.

What is the mechanism of action of CJC-1295 with DAC?

Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The maleimide-based Drug Affinity Complex (DAC) tail covalently binds serum albumin, extending half-life from minutes to days. Stimulates pulsatile GH secretion that elevates baseline IGF-1. For female hormonal and cyclical applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Binds the GHRH receptor on somatotrophs to stimulate endogenous GH release. The female physiology interpretation focuses on the pathway-level detail rather than on any single high-level summary.

Should I cycle CJC-1295 with DAC?

Standard cycle for CJC-1295 with DAC is 8–12 weeks of 1-2x weekly 1-2 mg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to CJC-1295 with DAC's ~6-8 days (with DAC) half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Clinical Protocol

Start a CJC-1295 with DAC Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified CJC-1295 with DAC and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: ~3367 Da
Sequence length: 30 aa
Half-life: ~6-8 days (with DAC)
WADA: Banned (S2 class)
FDA: Unapproved
Research: Phase II human data; widely used off-label

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 with DAC unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for CJC-1295 with DAC

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised